Dataset: Expression data from primary central nervous system lymphoma (PCNSL) patients

This study aimed to define the genes associated with PCNSL patient survival. Expression profiling was performed on 34 PCNSLs. A gene...

Registered by ArrayExpress Uploader

View Dataset

This study aimed to define the genes associated with PCNSL patient survival. Expression profiling was performed on 34 PCNSLs. A gene classifier was developed. Thirty-four PCNSL patients were selected for RNA extraction and hybridization on Affymetrix microarrays.

Species:: human
Samples:: 34
Source:: E-GEOD-34771
PubMed:: 22908096
Updated:: Dec.12, 2014
Registered:: Jul.12, 2014

Factors: (via ArrayExpress)

Sample	KARNOFSKY PERFORMANCE STATUS KPS	AGE	SEX	THERAPY	OUTCOME	SURVIVAL TIME
GSM854975	60	68 years	female	HD-MTX chemotherapy	alive	less than 1 year
GSM854974	50	67 years	female	HD-MTX chemotherapy	alive	1-2 years
GSM854973	70	64 years	male	HD-MTX chemotherapy	alive	more than 3 years
GSM854972	70	72 years	female	HD-MTX chemotherapy	alive	more than 3 years
GSM85497	40	71 years	female	HD-MTX chemotherapy	dead	1-2 years
GSM854970	70	50 years	male	HD-MTX chemotherapy	alive	more than 3 years
GSM854969	50	68 years	female	HD-MTX chemotherapy	dead	2-3 years
GSM854968	50	44 years	male	HD-MTX chemotherapy	dead	2-3 years
GSM854967	60	76 years	male	HD-MTX chemotherapy	dead	1-2 years
GSM854966	80	63 years	male	HD-MTX chemotherapy	dead	2-3 years
GSM854965	80	64 years	male	HD-MTX chemotherapy	survival	more than 3 years
GSM854964	50	59 years	female	HD-MTX chemotherapy	dead	more than 3 years
GSM854963	50	63 years	male	not specified	survival	less than 1 year
GSM854962	60	57 years	male	HD-MTX chemotherapy	dead	less than 1 year
GSM85496	40	68 years	female	HD-MTX chemotherapy	survival	less than 1 year
GSM854960	100	62 years	male	HD-MTX-containing polychemotherapy	dead	more than 3 years
GSM854959	60	68 years	female	HD-MTX-containing polychemotherapy	dead	more than 3 years
GSM854958	90	57 years	female	HD-MTX chemotherapy	dead	2-3 years
GSM854957	70	74 years	male	HD-MTX chemotherapy	survival	more than 3 years
GSM854956	70	59 years	female	HD-MTX-containing polychemotherapy	dead	1-2 years
GSM854955	90	68 years	female	HD-MTX-containing polychemotherapy	dead	more than 3 years
GSM854954	70	47 years	male	not specified	dead	more than 3 years
GSM854953	80	58 years	male	HD-MTX-containing polychemotherapy	alive	more than 3 years
GSM854952	50	69 years	male	not specified	dead	more than 3 years
GSM85495	100	68 years	male	HD-MTX-containing polychemotherapy	dead	less than 1 year
GSM854950	60	66 years	female	HD-MTX-containing polychemotherapy	dead	more than 3 years
GSM854949	100	70 years	female	HD-MTX-containing polychemotherapy	dead	2-3 years
GSM854948	70	70 years	male	HD-MTX-containing polychemotherapy	dead	2-3 years
GSM854947	70	63 years	female	HD-MTX-containing polychemotherapy	dead	1-2 years
GSM854946	80	71 years	female	HD-MTX-containing polychemotherapy	alive	more than 3 years
GSM854945	100	62 years	male	not specified	dead	1-2 years
GSM854944	70	55 years	male	HD-MTX-containing polychemotherapy	dead	less than 1 year
GSM854943	70	73 years	male	HD-MTX-containing polychemotherapy	dead	more than 3 years
GSM854942	60	65 years	male	HD-MTX-containing polychemotherapy	dead	more than 3 years